Determinants of increased cardiovascular disease in obesity and metabolic syndrome

Current Medicinal Chemistry

Volumn 18, Issue 34, 2011, Pages 5267-5280

  Vazzana, N ^a   Santilli, F ^a   Sestili, S ^a   Cuccurullo, C ^a   Davi G ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Adipokines; Cardiovascular disease; Inflammation; Insulin resistance; Metabolic syndrome; Obesity; Oxidative stress; Platelet activation

Indexed keywords

ACARBOSE; ADIPONECTIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LORCASERIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PADGEM PROTEIN; RESISTIN; RETINOL BINDING PROTEIN 4; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASPIN;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; ATHEROSCLEROSIS; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID STORAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; THROMBOCYTE ACTIVATION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC SYNDROME X; OBESITY;

EID: 82255169296     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798184299     Document Type: Article

References (173)

1. Flegal, K. M.; Carroll, M. D.; Ogden, C. L.; Curtin, L. R. Prevalence and trends in obesity among US adults, 1999-2008. Jama. 2010, 303, 235-241.
2. Bonora, E. The metabolic syndrome and cardiovascular disease. Ann Med. 2006, 38, 64-80. (Pubitemid 43177789)
3. Alberti, K. G.; Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998, 15, 539-553. (Pubitemid 28319935)
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jaama. 2001, 285, 2486-2497.
5. Balkau, B.; Charles, M. A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999, 16, 442-443.
6. Alberti, K. G.; Zimmet, P.; Shaw, J. The metabolic syndrome-a new worldwide definition. Lancet. 2005, 366, 1059-1062. (Pubitemid 41338752)
7. Alberti, K. G. M. M.; Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z.; Cleeman, J. I.; Donato, K. A.; Fruchart, J.-C.; James, W. P. T.; Loria, C. M.; Smith, S. C. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120, 1640-1645.
8. Ford, E. S.; Giles, W. H.; Dietz, W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Jama. 2002, 287, 356-359. (Pubitemid 34251969)
9. Shoelson, S. E.; Lee, J.; Goldfine, A. B. Inflammation and insulin resistance. J Clin Invest. 2006, 116, 1793-1801. (Pubitemid 44033299)
10. Klein, S.; Allison, D. B.; Heymsfield, S. B.; Kelley, D. E.; Leibel, R. L.; Nonas, C.; Kahn, R. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007, 30, 1647-1652. (Pubitemid 46871194)
11. Arnlov, J.; Ingelsson, E.; Sundstrom, J.; Lind, L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010, 121, 230-236.
12. Romero-Corral, A.; Somers, V. K.; Sierra-Johnson, J.; Korenfeld, Y.; Boarin, S.; Korinek, J.; Jensen, M. D.; Parati, G.; Lopez-Jimenez, F. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010, 31, 737-746.
13. Meigs, J. B.; Wilson, P. W. F.; Fox, C. S.; Vasan, R. S.; Nathan, D. M.; Sullivan, L. M.; D'Agostino, R. B. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006, 91, 2906-2912. (Pubitemid 44271734)
14. Brochu, M.; Tchernof, A.; Dionne, I. J.; Sites, C. K.; Eltabbakh, G. H.; Sims, E. A.; Poehlman, E. T. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001, 86, 1020-1025. (Pubitemid 32322976)
15. Bluher, M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol. 2010, 21, 38-43.
16. Berrington de Gonzalez, A.; Hartge, P.; Cerhan, J. R.; Flint, A. J.; Hannan, L.; MacInnis, R. J.; Moore, S. C.; Tobias, G. S.; Anton-Culver, H.; Freeman, L. B.; Beeson, W. L.; Clipp, S. L.; English, D. R.; Folsom, A. R.; Freedman, D. M.; Giles, G.; Hakansson, N.; Henderson, K. D.; Hoffman-Bolton, J.; Hoppin, J. A.; Koenig, K. L.; Lee, I. M.; Linet, M. S.; Park, Y.; Pocobelli, G.; Schatzkin, A.; Sesso, H. D.; Weiderpass, E.; Willcox, B. J.; Wolk, A.; Zeleniuch-Jacquotte, A.; Willett, W. C.; Thun, M. J. Body-mass index and mortality among 1. 46 million white adults. N Engl J Med. 2010, 363, 2211-2219.
17. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352, 1685-1695.
18. Zhang, Y.; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J. M. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994, 372, 425-432. (Pubitemid 24365442)
19. Gustafson, B.; Hammarstedt, A.; Andersson, C. X.; Smith, U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007, 27, 2276-2283. (Pubitemid 350203940)
20. Kaptoge, S.; Di Angelantonio, E.; Lowe, G.; Pepys, M. B.; Thompson, S. G.; Collins, R.; Danesh, J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Laancet. 2010, 375, 132-140.
21. Schunkert, H.; Samani, N. J. Elevated C-reactive protein in atherosclerosis-chicken or egg? N Engl J Med. 2008, 359, 1953-1955.
22. Johnson, B. D.; Kip, K. E.; Marroquin, O. C.; Ridker, P. M.; Kelsey, S. F.; Shaw, L. J.; Pepine, C. J.; Sharaf, B.; Bairey Merz, C. N.; Sopko, G.; Olson, M. B.; Reis, S. E. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004, 109, 726-732. (Pubitemid 38222891)
23. Yang, R.-Z.; Lee, M.-J.; Hu, H.; Pollin, T. I.; Ryan, A. S.; Nicklas, B. J.; Snitker, S.; Horenstein, R. B.; Hull, K.; Goldberg, N. H.; Goldberg, A. P.; Shuldiner, A. R.; Fried, S. K.; Gong, D.-W. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006, 3, e287.
24. Steppan, C. M.; Bailey, S. T.; Bhat, S.; Brown, E. J.; Banerjee, R. R.; Wright, C. M.; Patel, H. R.; Ahima, R. S.; Lazar, M. A. The hormone resistin links obesity to diabetes. Nature. 2001, 409, 307-312. (Pubitemid 32151228)
25. Meier, U.; Gressner, A. M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004, 50, 1511-1525. (Pubitemid 39121218)
26. Reilly, M. P.; Lehrke, M.; Wolfe, M. L.; Rohatgi, A.; Lazar, M. A.; Rader, D. J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005, 111, 932-939. (Pubitemid 40279897)
27. Pai, J. K.; Pischon, T.; Ma, J.; Manson, J. E.; Hankinson, S. E.; Joshipura, K.; Curhan, G. C.; Rifai, N.; Cannuscio, C. C.; Stampfer, M. J.; Rimm, E. B. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004, 351, 2599-2610. (Pubitemid 39628581)
28. Gualillo, O.; Gonzalez-Juanatey, J. R.; Lago, F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med. 2007, 17, 275-283. (Pubitemid 350087698)
29. Chandran, M.; Phillips, S. A.; Ciaraldi, T.; Henry, R. R. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003, 26, 2442-2450. (Pubitemid 36993340)
30. Rabe, K.; Lehrke, M.; Parhofer, K. G.; Broedl, U. C. Adipokines and insulin resistance. Mol Med. 2008, 14, 741-751.
31. Maury, E.; Brichard, S. M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010, 314, 1-16.
32. Kazumi, T.; Kawaguchi, A.; Sakai, K.; Hirano, T.; Yoshino, G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002, 25, 971-976. (Pubitemid 41110480)
33. Kato, H.; Kashiwagi, H.; Shiraga, M.; Tadokoro, S.; Kamae, T.; Ujiie, H.; Honda, S.; Miyata, S.; Ijiri, Y.; Yamamoto, J.; Maeda, N.; Funahashi, T.; Kurata, Y.; Shimomura, I.; Tomiyama, Y.; Kanakura, Y. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006, 26, 224-230. (Pubitemid 43732254)
34. Koh, K. K.; Park, S. M.; Quon, M. J. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008, 117, 3238-3249.
35. Leyva, F.; Godsland, I. F.; Ghatei, M.; Proudler, A. J.; Aldis, S.; Walton, C.; Bloom, S.; Stevenson, J. C. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol. 1998, 18, 928-933. (Pubitemid 28272587)
36. Wallace, A. M.; McMahon, A. D.; Packard, C. J.; Kelly, A.; Shepherd, J.; Gaw, A.; Sattar, N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001, 104, 3052-3056. (Pubitemid 34014056)
37. Piatti, P.; Di Mario, C.; Monti, L. D.; Fragasso, G.; Sgura, F.; Caumo, A.; Setola, E.; Lucotti, P.; Galluccio, E.; Ronchi, C.; Origgi, A.; Zavaroni, I.; Margonato, A.; Colombo, A. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003, 108, 2074-2081. (Pubitemid 37337582)
38. Soderberg, S.; Ahren, B.; Stegmayr, B.; Johnson, O.; Wiklund, P. G.; Weinehall, L.; Hallmans, G.; Olsson, T. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke. 1999, 30, 328-337. (Pubitemid 29071798)
39. Guagnano, M. T.; Romano, M.; Falco, A.; Nutini, M.; Marinopiccoli, M.; Manigrasso, M. R.; Basili, S.; Davi, G. Leptin increase is associated with markers of the hemostatic system in obese healthy women. J Thromb Haemost. 2003, 1, 2330-2334.
40. Yang, Q.; Graham, T. E.; Mody, N.; Preitner, F.; Peroni, O. D.; Zabolotny, J. M.; Kotani, K.; Quadro, L.; Kahn, B. B. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005, 436, 356-362. (Pubitemid 41065039)
41. Kowalska, I.; Straczkowski, M.; Adamska, A.; Nikolajuk, A.; Karczewska-Kupczewska, M.; Otziomek, E.; Gorska, M. Serum retinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance. J Clin Endocrinol Metab. 2008, 93, 2786-2789. (Pubitemid 352008552)
42. Graham, T. E.; Yang, Q.; Bluher, M.; Hammarstedt, A.; Ciaraldi, T. P.; Henry, R. R.; Wason, C. J.; Oberbach, A.; Jansson, P.-A.; Smith, U.; Kahn, B. B. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006, 354, 2552-2563. (Pubitemid 43882351)
43. Fukuhara, A.; Matsuda, M.; Nishizawa, M.; Segawa, K.; Tanaka, M.; Kishimoto, K.; Matsuki, Y.; Murakami, M.; Ichisaka, T.; Murakami, H.; Watanabe, E.; Takagi, T.; Akiyoshi, M.; Ohtsubo, T.; Kihara, S.; Yamashita, S.; Makishima, M.; Funahashi, T.; Yamanaka, S.; Hiramatsu, R.; Matsuzawa, Y.; Shimomura, I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005, 307, 426-430. (Pubitemid 40139988)
44. Dahl, T. B.; Yndestad, A.; Skjelland, M.; oie, E.; Dahl, A.; Michelsen, A.; Damas, J. K.; Tunheim, S. H.; Ueland, T.; Smith, C.; Bendz, B.; Tonstad, S.; Gullestad, L.; Froland, S. S.; Krohg-Sorensen, K.; Russell, D.; Aukrust, P.; Halvorsen, B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007, 115, 972-980. (Pubitemid 46328290)
45. Yang, R.-Z.; Lee, M.-J.; Hu, H.; Pray, J.; Wu, H.-B.; Hansen, B. C.; Shuldiner, A. R.; Fried, S. K.; McLenithan, J. C.; Gong, D.-W. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006, 290, E1253-1261. (Pubitemid 43847911)
46. Goralski, K. B.; McCarthy, T. C.; Hanniman, E. A.; Zabel, B. A.; Butcher, E. C.; Parlee, S. D.; Muruganandan, S.; Sinal, C. J. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007, 282, 28175-28188. (Pubitemid 47529521)
47. Hida, K.; Wada, J.; Eguchi, J.; Zhang, H.; Baba, M.; Seida, A.; Hashimoto, I.; Okada, T.; Yasuhara, A.; Nakatsuka, A.; Shikata, K.; Hourai, S.; Futami, J.; Watanabe, E.; Matsuki, Y.; Hiramatsu, R.; Akagi, S.; Makino, H.; Kanwar, Y. S. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005, 102, 10610-10615. (Pubitemid 41061602)
48. Youn, B.-S.; Kloting, N.; Kratzsch, J.; Lee, N.; Park, J. W.; Song, E.-S.; Ruschke, K.; Oberbach, A.; Fasshauer, M.; Stumvoll, M.; Bluher, M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008, 57, 372-377.
49. Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005, 111, 1448-1454. (Pubitemid 40396812)
50. Evans, J. L.; Goldfine, I. D.; Maddux, B. A.; Grodsky, G. M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002, 23, 599-622. (Pubitemid 35191625)
51. Keaney, J. F.; Larson, M. G.; Vasan, R. S.; Wilson, P. W. F.; Lipinska, I.; Corey, D.; Massaro, J. M.; Sutherland, P.; Vita, J. A.; Benjamin, E. J. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003, 23, 434-439. (Pubitemid 36337219)
52. Patrono, C.; Falco, A.; Davi, G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol. 2005, 5, 198-203. (Pubitemid 40378753)
53. Davì, G.; Falco, A. Oxidant stress, inflammation and atherogenesis. Lupus. 2005, 14, 760-764. (Pubitemid 41413307)
54. Davi, G.; Guagnano, M. T.; Ciabattoni, G.; Basili, S.; Falco, A.; Marinopiccoli, M.; Nutini, M.; Sensi, S.; Patrono, C. Platelet activation in obese women: role of inflammation and oxidant stress. Jama. 2002, 288, 2008-2014. (Pubitemid 35204691)
55. Urakawa, H.; Katsuki, A.; Sumida, Y.; Gabazza, E. C.; Murashima, S.; Morioka, K.; Maruyama, N.; Kitagawa, N.; Tanaka, T.; Hori, Y.; Nakatani, K.; Yano, Y.; Adachi, Y. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab. 2003, 88, 4673-4676. (Pubitemid 37357510)
56. Ferroni, P.; Basili, S.; Paoletti, V.; Davã, G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr Metab Cardiovasc Dis. 2006, 16, 222-233.
57. Guagnano, M. T.; Ferroni, P.; Santilli, F.; Paoletti, V.; Manigrasso, M. R.; Pescara, L.; Cuccurullo, C.; Ciabattoni, G.; Davi, G. Determinants of platelet activation in hypertensives with microalbuminuria. Free Radic Biol Med. 2009, 46, 922-927.
58. Davi, G.; Ciabattoni, G.; Consoli, A.; Mezzetti, A.; Falco, A.; Santarone, S.; Pennese, E.; Vitacolonna, E.; Bucciarelli, T.; Costantini, F.; Capani, F.; Patrono, C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999, 99, 224-229. (Pubitemid 29056363)
59. Davi, G.; Chiarelli, F.; Santilli, F.; Pomilio, M.; Vigneri, S.; Falco, A.; Basili, S.; Ciabattoni, G.; Patrono, C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003, 107, 3199-3203. (Pubitemid 36793091)
60. Davi, G.; Falco, A.; Patrono, C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal. 2005, 7, 256-268. (Pubitemid 40187942)
61. Monnier, L.; Mas, E.; Ginet, C.; Michel, F.; Villon, L.; Cristol, J.-P.; Colette, C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama. 2006, 295, 1681-1687.
62. Santilli, F.; Formoso, G.; Sbraccia, P.; Averna, M.; Miccoli, R.; Di Fulvio, P.; Ganci, A.; Pulizzi, N.; Lattanzio, S.; Ciabattoni, G.; Consoli, A.; Lauro, R.; Patrono, C.; DavÌ, G. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost. 2010, 8, 828-837.
63. De Cristofaro, R.; Rocca, B.; Vitacolonna, E.; Falco, A.; Marchesani, P.; Ciabattoni, G.; Landolfi, R.; Patrono, C.; Davì, G. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost. 2003, 1, 250-256.
64. Goldin, A.; Beckman, J. A.; Schmidt, A. M.; Creager, M. A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006, 114, 597-605. (Pubitemid 44199649)
65. Yan, S. F.; Ramasamy, R.; Schmidt, A. M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008, 4, 285-293. (Pubitemid 351571138)
66. Santilli, F.; Vazzana, N.; Bucciarelli, L. G.; Davi, G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem. 2009, 16, 940-952.
67. Vazzana, N.; Santilli, F.; Cuccurullo, C.; Davi, G. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009, 4, 389-401.
68. Devangelio, E.; Santilli, F.; Formoso, G.; Ferroni, P.; Bucciarelli, L.; Michetti, N.; Clissa, C.; Ciabattoni, G.; Consoli, A.; Davi, G. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med. 2007, 43, 511-518. (Pubitemid 47058227)
69. Davi, G.; Alessandrini, P.; Mezzetti, A.; Minotti, G.; Bucciarelli, T.; Costantini, F.; Cipollone, F.; Bon, G. B.; Ciabattoni, G.; Patrono, C. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997, 17, 3230-3235. (Pubitemid 28016082)
70. Ferroni, P.; Basili, S.; Falco, A.; Davi, G. Oxidant stress and platelet activation in hypercholesterolemia. Antioxid Redox Signal. 2004, 6, 747-756. (Pubitemid 38890792)
71. Puccetti, L.; Santilli, F.; Pasqui, A. L.; Lattanzio, S.; Liani, R.; Ciani, F.; Ferrante, E.; Ciabattoni, G.; Scarpini, F.; Ghezzi, A.; Auteri, A.; Davi, G. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. A th ero scle ro sis. 2011, 214, 122-128.
72. Ferroni, P.; Basili, S.; Davì, G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol. 2003, 1, 157-169.
73. Holvoet, P.; Kritchevsky, S. B.; Tracy, R. P.; Mertens, A.; Rubin, S. M.; Butler, J.; Goodpaster, B.; Harris, T. B. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004, 53, 1068-1073. (Pubitemid 38436620)
74. Heslop, C. L.; Frohlich, J. J.; Hill, J. S. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol. 2010, 55, 1102-1109.
75. Shimada, K.; Mokuno, H.; Matsunaga, E.; Miyazaki, T.; Sumiyoshi, K.; Miyauchi, K.; Daida, H. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis. 2004, 174, 343-347. (Pubitemid 38597092)
76. Santilli, F.; Bucciarelli, L.; Noto, D.; Cefalu, A. B.; Davi, V.; Ferrante, E.; Pettinella, C.; Averna, M. R.; Ciabattoni, G.; Davi, G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med. 2007, 43, 1255-1262. (Pubitemid 47429934)
77. Cangemi, R.; Angelico, F.; Loffredo, L.; Del Ben, M.; Pignatelli, P.; Martini, A.; Violi, F. Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. Free Radic Biol Med. 2007, 43, 853-859. (Pubitemid 47102131)
78. Davi, G.; Patrono, C. Platelet activation and atherothrombosis. N Engl J Med. 2007, 357, 2482-2494.
79. Pignatelli, P.; Carnevale, R.; Di Santo, S.; Bartimoccia, S.; Sanguigni, V.; Lenti, L.; Finocchi, A.; Mendolicchio, L.; Soresina, A. R.; Plebani, A.; Violi, F. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol. 2011, 31, 423-434.
80. Sanyal, A. J.; Chalasani, N.; Kowdley, K. V.; McCullough, A.; Diehl, A. M.; Bass, N. M.; Neuschwander-Tetri, B. A.; Lavine, J. E.; Tonascia, J.; Unalp, A.; Van Natta, M.; Clark, J.; Brunt, E. M.; Kleiner, D. E.; Hoofnagle, J. H.; Robuck, P. R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362, 1675-1685.
81. Angelico, F.; Del Ben, M.; Conti, R.; Francioso, S.; Feole, K.; Fiorello, S.; Cavallo, M. G.; Zalunardo, B.; Lirussi, F.; Alessandri, C.; Violi, F. Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2005, 90, 1578-1582. (Pubitemid 40464021)
82. Marin, J. M.; Carrizo, S. J.; Vicente, E.; Agusti, A. G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005, 365, 1046-1053. (Pubitemid 40386782)
83. Drager, L. F.; Polotsky, V. Y.; Lorenzi-Filho, G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011, 140, 534-542.
84. Yuan, G.; Nanduri, J.; Khan, S.; Semenza, G. L.; Prabhakar, N. R. Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol. 2008, 217, 674-685.
85. Tan, K. C.; Chow, W. S.; Lam, J. C.; Lam, B.; Wong, W. K.; Tam, S.; Ip, M. S. HDL dysfunction in obstructive sleep apnea. Atherosclerosis. 2006, 184, 377-382. (Pubitemid 43049723)
86. Angelico, F.; del Ben, M.; Augelletti, T.; de Vita, R.; Roma, R.; Violi, F.; Fabiani, M. Obstructive sleep apnoea syndrome and the metabolic syndrome in an internal medicine setting. Eur J Intern Med. 2010, 21, 191-195.
87. Ceriello, A.; Motz, E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24, 816-823. (Pubitemid 38620857)
88. Steinberg, D.; Witztum, J. L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002, 105, 2107-2111. (Pubitemid 34465275)
89. Davi, G.; Santilli, F.; Patrono, C. Nutraceuticals in diabetes and metabolic syndrome. Cardiovasc Ther. 2010, 28, 216-226.
90. Roberts, L. J.; Oates, J. A.; Linton, M. F.; Fazio, S.; Meador, B. P.; Gross, M. D.; Shyr, Y.; Morrow, J. D. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med. 2007, 43, 1388-1393. (Pubitemid 47532362)
91. Kissebah, A. H.; Krakower, G. R. Regional adiposity and morbidity. Physiol Rev. 1994, 74, 761-811. (Pubitemid 24328939)
92. Jeppesen, J.; Hansen, T. W.; Rasmussen, S.; Ibsen, H.; Torp-Pedersen, C.; Madsbad, S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007, 49, 2112-2119. (Pubitemid 46771048)
93. Pellme, F.; Smith, U.; Funahashi, T.; Matsuzawa, Y.; Brekke, H.; Wiklund, O.; Taskinen, M. R.; Jansson, P. A. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes. 2003, 52, 1182-1186. (Pubitemid 36523354)
94. Kahn, B. B.; Flier, J. S. Obesity and insulin resistance. J Clin Invest. 2000, 106, 473-481. (Pubitemid 30666380)
95. Manigrasso, M. R.; Ferroni, P.; Santilli, F.; Taraborelli, T.; Guagnano, M. T.; Michetti, N.; Davi, G. Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab. 2005, 90, 5876-5879. (Pubitemid 41415505)
96. Cypess, A. M.; Lehman, S.; Williams, G.; Tal, I.; Rodman, D.; Goldfine, A. B.; Kuo, F. C.; Palmer, E. L.; Tseng, Y.-H.; Doria, A.; Kolodny, G. M.; Kahn, C. R. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009, 360, 1509-1517.
97. Kim, J.-a.; Montagnani, M.; Koh, K. K.; Quon, M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006, 113, 1888-1904. (Pubitemid 43739401)
98. Basta, G.; Sironi, A. M.; Lazzerini, G.; Del Turco, S.; Buzzigoli, E.; Casolaro, A.; Natali, A.; Ferrannini, E.; Gastaldelli, A. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006, 91, 4628-4634. (Pubitemid 44833448)
99. Koyama, H.; Shoji, T.; Yokoyama, H.; Motoyama, K.; Mori, K.; Fukumoto, S.; Emoto, M.; Shoji, T.; Tamei, H.; Matsuki, H.; Sakurai, S.; Yamamoto, Y.; Yonekura, H.; Watanabe, T.; Yamamoto, H.; Nishizawa, Y. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005, 25, 2587-2593. (Pubitemid 43732283)
100. Kahn, B. B.; McGraw, T. E. Rosiglitazone, PPARg, and type 2 diabetes. N Engl J Med. 2010, 363, 2667-2669.
101. Anfossi, G.; Russo, I.; Trovati, M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis. 2009, 19, 440-449.
102. De Pergola, G.; Pannacciulli, N.; Coviello, M.; Scarangella, A.; Di Roma, P.; Caringella, M.; Venneri, M. T.; Quaranta, M.; Giorgino, R. sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors. Nutr Metab Cardiovasc Dis. 2008, 18, 227-232. (Pubitemid 351384657)
103. Sato, C.; Shikata, K.; Hirota, D.; Sasaki, M.; Nishishita, S.; Miyamoto, S.; Kodera, R.; Ogawa, D.; Tone, A.; Kataoka, H. U.; Wada, J.; Kajitani, N.; Makino, H. P-selectin glycoprotein ligand-1 deficiency is protective against obesity-related insulin resistance. Diabetes. 2011, 60, 189-199.
104. Angelico, F.; Alessandri, C.; Ferro, D.; Pignatelli, P.; Del Ben, M.; Fiorello, S.; Cangemi, R.; Loffredo, L.; Violi, F. Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. Diabetologia. 2006, 49, 1169-1174.
105. Santilli, F.; Davì, G.; Consoli, A.; Cipollone, F.; Mezzetti, A.; Falco, A.; Taraborelli, T.; Devangelio, E.; Ciabattoni, G.; Basili, S.; Patrono, C. Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2006, 47, 391-397. (Pubitemid 43063260)
106. Missiou, A.; Wolf, D.; Platzer, I.; Ernst, S.; Walter, C.; Rudolf, P.; Zirlik, K.; Kostlin, N.; Willecke, F. K.; Munkel, C.; Schonbeck, U.; Libby, P.; Bode, C.; Varo, N.; Zirlik, A. CD40L induces inflammation and adipogenesis in adipose cells-a potential link between metabolic and cardiovascular disease. Thromb Haemost. 2010, 103, 788-796.
107. Poggi, M.; Jager, J.; Paulmyer-Lacroix, O.; Peiretti, F.; Gremeaux, T.; Verdier, M.; Grino, M.; Stepanian, A.; Msika, S.; Burcelin, R.; de Prost, D.; Tanti, J. F.; Alessi, M. C. The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia. 2009, 52, 1152-1163.
108. Bath, P. M.; Butterworth, R. J. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996, 7, 157-161. (Pubitemid 26167943)
109. Vizioli, L.; Muscari, S.; Muscari, A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009, 63, 1509-1515.
110. Coban, E.; Ozdogan, M.; Yazicioglu, G.; Akcit, F. The mean platelet volume in patients with obesity. Int J Clin Pract. 2005, 59, 981-982.
111. Coban, E.; Yilmaz, A.; Sari, R. The effect of weight loss on the mean platelet volume in obese patients. Platelets. 2007, 18, 212-216. (Pubitemid 46744121)
112. Vaduganathan, M.; Alviar, C. L.; Arikan, M. E.; Tellez, A.; Guthikonda, S.; DeLao, T.; Granada, J. F.; Kleiman, N. S.; Ballantyne, C. M.; Lev, E. I. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008, 156, 1002. e1001-1002.e1007.
113. Tavil, Y.; Sen, N.; Yazici, H. U.; Hizal, F.; Abaci, A.; Cengel, A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res. 2007, 120, 245-250. (Pubitemid 46759554)
114. Merten, M.; Pakala, R.; Thiagarajan, P.; Benedict, C. R. Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation. 1999, 99, 2577-2582. (Pubitemid 29228290)
115. Arteaga, R. B.; Chirinos, J. A.; Soriano, A. O.; Jy, W.; Horstman, L.; Jimenez, J. J.; Mendez, A.; Ferreira, A.; de Marchena, E.; Ahn, Y. S. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol. 2006, 98, 70-74. (Pubitemid 43902682)
116. Serebruany, V. L.; Malinin, A.; Ong, S.; Atar, D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis. 2008, 25, 207-213. (Pubitemid 351595984)
117. Murakami, T.; Horigome, H.; Tanaka, K.; Nakata, Y.; Ohkawara, K.; Katayama, Y.; Matsui, A. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res. 2007, 119, 45-53. (Pubitemid 44716205)
118. Falcon, C.; Pfliegler, G.; Deckmyn, H.; Vermylen, J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun. 1988, 157, 1190-1196. (Pubitemid 19025983)
119. Trovati, M.; Anfossi, G.; Cavalot, F.; Massucco, P.; Mularoni, E.; Emanuelli, G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes. 1988, 37, 780-786. (Pubitemid 19043187)
120. Trovati, M.; Anfossi, G.; Massucco, P.; Mattiello, L.; Costamagna, C.; Piretto, V.; Mularoni, E.; Cavalot, F.; Bosia, A.; Ghigo, D. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate. Diabetes. 1997, 46, 742-749. (Pubitemid 27188249)
121. Trovati, M.; Mularoni, E. M.; Burzacca, S.; Ponziani, M. C.; Massucco, P.; Mattiello, L.; Piretto, V.; Cavalot, F.; Anfossi, G. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes. 1995, 44, 1318-1322.
122. Russo, I.; Traversa, M.; Bonomo, K.; De Salve, A.; Mattiello, L.; Del Mese, P.; Doronzo, G.; Cavalot, F.; Trovati, M.; Anfossi, G. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity. 2010, 18, 788-797.
123. Basili, S.; Pacini, G.; Guagnano, M. T.; Manigrasso, M. R.; Santilli, F.; Pettinella, C.; Ciabattoni, G.; Patrono, C.; Davi, G. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol. 2006, 48, 2531-2538. (Pubitemid 44881227)
124. Nicholls, S. J.; Tuzcu, E. M.; Wolski, K.; Bayturan, O.; Lavoie, A.; Uno, K.; Kupfer, S.; Perez, A.; Nesto, R.; Nissen, S. E. Lowering the
125. Knowler, W. C.; Barrett-Connor, E.; Fowler, S. E.; Hamman, R. F.; Lachin, J. M.; Walker, E. A.; Nathan, D. M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346, 393-403. (Pubitemid 34437694)
126. Williamson, D. F.; Thompson, T. J.; Thun, M.; Flanders, D.; Pamuk, E.; Byers, T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000, 23, 1499-1504.
127. Hu, F. B.; Manson, J. E.; Stampfer, M. J.; Colditz, G.; Liu, S.; Solomon, C. G.; Willett, W. C. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001, 345, 790-797.
128. Esposito, K.; Pontillo, A.; Di Palo, C.; Giugliano, G.; Masella, M.; Marfella, R.; Giugliano, D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. Jama. 2003, 289, 1799-1804. (Pubitemid 37430249)
129. You, T.; Berman, D. M.; Ryan, A. S.; Nicklas, B. J. Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab. 2004, 89, 1739-1746. (Pubitemid 38507928)
130. Hamdy, O.; Ledbury, S.; Mullooly, C.; Jarema, C.; Porter, S.; Ovalle, K.; Moussa, A.; Caselli, A.; Caballero, A. E.; Economides, P. A.; Veves, A.; Horton, E. S. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care. 2003, 26, 2119-2125. (Pubitemid 41184262)
131. Esposito, K.; Marfella, R.; Ciotola, M.; Di Palo, C.; Giugliano, F.; Giugliano, G.; D'Armiento, M.; D'Andrea, F.; Giugliano, D. Effect of a mediterraneanstyle diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. Jama. 2004, 292, 1440-1446. (Pubitemid 39258336)
132. Brook, R. D. Obesity, weight loss, and vascular function. Endocrine. 2006, 29, 21-25. (Pubitemid 43780343)
133. Gresele, P.; Cerletti, C.; Guglielmini, G.; Pignatelli, P.; de Gaetano, G.; Violi, F. Effects of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem. 2011, 22, 201-211.
134. Astrup, A. Drug management of obesity-efficacy versus safety. N Engl J Med. 2010, 363, 288-290.
135. Wadden, T. A.; Berkowitz, R. I.; Womble, L. G.; Sarwer, D. B.; Phelan, S.; Cato, R. K.; Hesson, L. A.; Osei, S. Y.; Kaplan, R.; Stunkard, A. J. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005, 353, 2111-2120. (Pubitemid 41653103)
136. James, W. P. T.; Caterson, I. D.; Coutinho, W.; Finer, N.; Van Gaal, L. F.; Maggioni, A. P.; Torp-Pedersen, C.; Sharma, A. M.; Shepherd, G. M.; Rode, R. A.; Renz, C. L. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010, 363, 905-917.
137. Gelfand, E. V.; Cannon, C. P. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006, 47, 1919-1926.
138. Despres, J.-P.; Golay, A.; Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005, 353, 2121-2134. (Pubitemid 41653104)
139. Schafer, A.; Pfrang, J.; Neumuller, J.; Fiedler, S.; Ertl, G.; Bauersachs, J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol. 2008, 154, 1047-1054. (Pubitemid 351915060)
140. Wang, Q.; Perrard, X. D.; Perrard, J. L.; Mansoori, A.; Smith, C. W.; Ballantyne, C. M.; Wu, H. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Obesity. 2010, 19, 505-513.
141. Huang, N.-l.; Juang, J.-m.; Wang, Y.-h.; Hsueh, C.-h.; Liang, Y.-j.; Lin, J.-l.; Tsai, C.-t.; Lai, L.-p. Rimonabant inhibits TNF-a-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway. Acta Pharmacol Sin. 2010, 31, 1447-1453.
142. Sugamura, K.; Sugiyama, S.; Nozaki, T.; Matsuzawa, Y.; Izumiya, Y.; Miyata, K.; Nakayama, M.; Kaikita, K.; Obata, T.; Takeya, M.; Ogawa, H. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation. 2009, 119, 28-36.
143. Smith, S. R.; Weissman, N. J.; Anderson, C. M.; Sanchez, M.; Chuang, E.; Stubbe, S.; Bays, H.; Shanahan, W. R. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010, 363, 245-256.
144. Davidson, M. H.; Hauptman, J.; DiGirolamo, M.; Foreyt, J. P.; Halsted, C. H.; Heber, D.; Heimburger, D. C.; Lucas, C. P.; Robbins, D. C.; Chung, J.; Heymsfield, S. B. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Jama. 1999, 281, 235-242. (Pubitemid 29058112)
145. Hsieh, C.-J.; Wang, P.-W.; Liu, R.-T.; Tung, S.-C.; Chien, W.-Y.; Chen, J.-F.; Chen, C.-H.; Kuo, M.-C.; Hu, Y.-H. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract. 2005, 67, 78-83. (Pubitemid 40037733)
146. Bougoulia, M.; Triantos, A.; Koliakos, G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones. 2006, 5, 259-269.
147. Samuelsson, L.; Gottsater, A.; Lindgarde, F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab. 2003, 5, 195-201. (Pubitemid 36519353)
148. Desilets, A. R.; Dhakal-Karki, S.; Dunican, K. C. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother. 2008, 42, 817-826. (Pubitemid 351778088)
149. Despres, J. P. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab. 2003, 29, 6S53-61. (Pubitemid 37187091)
150. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352, 854-865.
151. Caballero, A. E.; Delgado, A.; Aguilar-Salinas, C. A.; Herrera, A. N.; Castillo, J. L.; Cabrera, T.; Gomez-Perez, F. J.; Rull, J. A. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2004, 89, 3943-3948. (Pubitemid 39071497)
152. Haffner, S.; Temprosa, M.; Crandall, J.; Fowler, S.; Goldberg, R.; Horton, E.; Marcovina, S.; Mather, K.; Orchard, T.; Ratner, R.; Barrett-Connor, E. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005, 54, 1566-1572.
153. Charles, M. A.; Morange, P.; Eschwege, E.; Andre, P.; Vague, P.; Juhan-Vague, I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 1998, 21, 1967-1972. (Pubitemid 28478302)
154. Fontbonne, A.; Charles, M. A.; Juhan-Vague, I.; Bard, J. M.; Andre, P.; Isnard, F.; Cohen, J. M.; Grandmottet, P.; Vague, P.; Safar, M. E.; Eschwege, E. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 1996, 19, 920-926. (Pubitemid 26301225)
155. Meaney, E.; Vela, A.; Samaniego, V.; Meaney, A.; Asbun, J.; Zempoalteca, J.-C.; Elisa, Z. N.; Emma, M. N.; Guzman, M.; Hicks, J.; Ceballos, G. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol. 2008, 35, 895-903. (Pubitemid 351951937)
156. Gargiulo, P.; Caccese, D.; Pignatelli, P.; Brufani, C.; De Vito, F.; Marino, R.; Lauro, R.; Violi, F.; Di Mario, U.; Sanguigni, V. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab Res Rev. 2002, 18, 156-159. (Pubitemid 34467306)
157. Leverve, X. M.; Guigas, B.; Detaille, D.; Batandier, C.; Koceir, E. A.; Chauvin, C.; Fontaine, E.; Wiernsperger, N. F. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab. 2003, 29, 6S88-94. (Pubitemid 37187095)
158. Formoso, G.; De Filippis, E. A.; Michetti, N.; Di Fulvio, P.; Pandolfi, A.; Bucciarelli, T.; Ciabattoni, G.; Nicolucci, A.; Davi, G.; Consoli, A. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev. 2008, 24, 231-237. (Pubitemid 351385541)
159. Abbasi, F.; Chu, J. W.; McLaughlin, T.; Lamendola, C.; Leary, E. T.; Reaven, G. M. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004, 53, 159-164. (Pubitemid 38168886)
160. Lund, S. S.; Tarnow, L.; Stehouwer, C. D. A.; Schalkwijk, C. G.; Teerlink, T.; Gram, J.; Winther, K.; Frandsen, M.; Smidt, U. M.; Pedersen, O.; Parving, H.-H.; Vaag, A. A. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol. 2008, 158, 631-641. (Pubitemid 351639600)
161. Chu, N. V.; Kong, A. P. S.; Kim, D. D.; Armstrong, D.; Baxi, S.; Deutsch, R.; Caulfield, M.; Mudaliar, S. R.; Reitz, R.; Henry, R. R.; Reaven, P. D. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002, 25, 542-549. (Pubitemid 41103350)
162. DeMaria, E. J. Bariatric surgery for morbid obesity. N Engl J Med. 2007, 356, 2176-2183. (Pubitemid 47010843)
163. Sjostrom, L.; Lindroos, A.-K.; Peltonen, M.; Torgerson, J.; Bouchard, C.; Carlsson, B.; Dahlgren, S.; Larsson, B.; Narbro, K.; Sjostrom, C. D.; Sullivan, M.; Wedel, H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004, 351, 2683-2693. (Pubitemid 39665322)
164. Adams, T. D.; Gress, R. E.; Smith, S. C.; Halverson, R. C.; Simper, S. C.; Rosamond, W. D.; Lamonte, M. J.; Stroup, A. M.; Hunt, S. C. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007, 357, 753-761. (Pubitemid 47295642)
165. Sjostrom, L.; Narbro, K.; Sjostrom, C. D.; Karason, K.; Larsson, B.; Wedel, H.; Lystig, T.; Sullivan, M.; Bouchard, C.; Carlsson, B.; Bengtsson, C.; Dahlgren, S.; Gummesson, A.; Jacobson, P.; Karlsson, J.; Lindroos, A.-K.; Lonroth, H.; Naslund, I.; Olbers, T.; Stenlof, K.; Torgerson, J.; Agren, G.; Carlsson, L. M. S. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007, 357, 741-752. (Pubitemid 47295641)
166. Kopp, H. P.; Kopp, C. W.; Festa, A.; Krzyzanowska, K.; Kriwanek, S.; Minar, E.; Roka, R.; Schernthaner, G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003, 23, 1042-1047. (Pubitemid 36713558)
167. Schernthaner, G.-H.; Kopp, H.-P.; Kriwanek, S.; Krzyzanowska, K.; Satler, M.; Koppensteiner, R.; Schernthaner, G. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocytechemoattractant-protein-1 in morbid obesity. Obes Surg. 2006, 16, 709-715. (Pubitemid 43874824)
168. Habib, P.; Scrocco, J. D.; Terek, M.; Vanek, V.; Mikolich, J. R. Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol. 2009, 104, 1251-1255.
169. Uzun, H.; Zengin, K.; Taskin, M.; Aydin, S.; Simsek, G.; Dariyerli, N. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg. 2004, 14, 659-665. (Pubitemid 38716588)
170. Schernthaner, G. H.; Kopp, H. P.; Krzyzanowska, K.; Kriwanek, S.; Koppensteiner, R.; Schernthaner, G. Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. Eur J Clin Invest. 2006, 36, 395-401. (Pubitemid 43742697)
171. Hanusch-Enserer, U.; Zorn, G.; Wojta, J.; Kopp, C. W.; Prager, R.; Koenig, W.; Schillinger, M.; Roden, M.; Huber, K. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J. 2009, 30, 1516-1524.
172. Ay, L.; Kopp, H. P.; Brix, J. M.; Ay, C.; Quehenberger, P.; Schernthaner, G. H.; Pabinger, I.; Schernthaner, G. Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost. 2010, 8, 759-765.
173. Tschoner, A.; Sturm, W.; Engl, J.; Kaser, S.; Laimer, M.; Laimer, E.; Klaus, A.; Patsch, J. R.; Ebenbichler, C. F. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutrition, Metabolism and Cardiovascular Diseases. 2010 Nov. 17. [Epub ahead of print].